Protocol Ledger

NCT05281471 · Phase III · RECRUITING

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Interventional Phase III clinical trial protocol NCT05281471 sponsored by Genelux in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-31 Enrollment: 186 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05281471
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)186 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05281471
Protocol FieldVerified Registry Value
NCT IdentifierNCT05281471
Consolidated Lead SponsorGenelux
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment186 participants (ESTIMATED)
Registered Start Date2022-08-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI